How does Olprinone (OLP) influence inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in the liver?

Label:chem

Topic
Inducible nitric oxide synthase (iNOS) and nitric oxide (NO) are key players in liver injury, contributing to inflammation and oxidative stress.
Answer
Olprinone (OLP) inhibited the induction of iNOS mRNA and reduced NO production in the liver of rats treated with partial hepatectomy and LPS. This effect was mediated through the suppression of NF-κB activation, a key signaling pathway involved in iNOS induction. OLP also reduced iNOS protein expression and NO production in primary cultured rat hepatocytes stimulated with interleukin-1β (IL-1β).
Return to Home Chemical List
Knowledge you may be interested in
What is the effect of Olprinone (OLP) on pro-inflammatory cytokines and chemokines in the liver? How does Olprinone (OLP) affect survival rates in rats subjected to partial hepatectomy and LPS treatment? What is the role of Olprinone (OLP) in hepatoprotection after partial hepatectomy and endotoxin-induced liver injury? What is the role of tacrolimus in preventing acute endothelial graft rejection after penetrating keratoplasty (PKP)? How does tacrolimus perform in treating adenoviral corneal subepithelial infiltrates (SEIs)? What are the advantages of using tacrolimus over corticosteroids in ocular graft-versus-host disease (GVHD)? How effective is tacrolimus in managing dry eye secondary to Sjogren syndrome? What are the common side effects of topical tacrolimus in ocular conditions? How does tacrolimus compare to other treatments in terms of efficacy for vernal keratoconjunctivitis (VKC)? What is the role of tacrolimus in the management of ocular surface diseases? What histopathological changes are observed in the liver after treatment with Olprinone (OLP)? How does Olprinone (OLP) affect NF-κB activation in hepatocytes? What are the potential clinical implications of using Olprinone (OLP) for hepatoprotection? What is the role of lanreotide in the treatment of gastroenteropancreatic neuroendocrine tumors (NETs)? How does lanreotide affect T cell function and survival in vitro? What are the in vivo effects of lanreotide on T cell gene expression in NET patients? Which specific genes were differentially expressed in responders versus non-responders before lanreotide treatment? How does lanreotide treatment affect T cell signaling pathways in vivo? How does the intranasal delivery of granisetron via nanostructured cubosomes improve the management of chemotherapy-induced emesis? What are the key components used to formulate granisetron-loaded cubosomes (GS-CBS)?